The evolving role of selenium in the treatment of Graves' disease and ophthalmopathy

Journal of Thyroid Research

Volumn 2012, Issue , 2012, Pages

  Duntas, Leonidas H ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALLOPURINOL; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTITHYROID AGENT; ASCORBIC ACID; B7 ANTIGEN; BETA CAROTENE; BIOLOGICAL MARKER; CD86 ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUTATHIONE PEROXIDASE; INTERLEUKIN 1; INTERLEUKIN 6; LEVOTHYROXINE; NICOTINAMIDE; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE; RITUXIMAB; SELENITE; SELENIUM; STEROID; THIAMAZOLE; THIONAMIDE DERIVATIVE; THYROTROPIN; THYROTROPIN RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CLINICAL ACTIVITY SCORE; ENZYME ACTIVITY; EYE DISEASE; GRAVES DISEASE; HUMAN; IMMUNOPATHOGENESIS; LOW DRUG DOSE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; REMISSION; REVIEW; SCORING SYSTEM; SYMPTOMATOLOGY; TH1 CELL; TH2 CELL; THYROIDECTOMY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84873616568     PISSN: 20908067     EISSN: 20420072     Source Type: Journal    
DOI: 10.1155/2012/736161     Document Type: Review

References (51)

1. Parry C. H., Collections from the Unpublished Medical Writings of the Late Caleb Hillier Parry 1982 2 London, UK Underwood
2. Graves R., Newly observed affection of the thyroid: clinical lectures. The London Medical and Surgical Journal 1835 7 516 517
3. von Basedow K., Exophthalmos durch Hypertrophie des Zellgewebes in der Augenhöhle. Wochenschr Heilkunde 1840 6 197 204
4. Weetman A. P., Graves' disease. The New England Journal of Medicine 2000 343 17 1236 1248 2-s2.0-0034718938 10.1056/NEJM200010263431707
5. Volpe R., Braverman L. E., Utiger R. D., Grave's disease. Pathogenesis. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text 1986 6th Philadelphia, Pa, USA J. B. Lippincott 648 657
6. Manji N., Carr-Smith J. D., Boelaert K., Allahabadia A., Armitage M., Chatterjee V. K., Lazarus J. H., Pearce S. H. S., Vaidya B., Gough S. C., Franklyn J. A., j.a.franklyn@bham.ac.uk Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. The Journal of Clinical Endocrinology & Metabolism 2006 91 12 4873 4880 10.1210/jc.2006-1402 (Pubitemid 44917321)
7. Chiovato L., Pinchera A., Stressful life events and Graves' disease. European Journal of Endocrinology 1996 134 6 680 682 2-s2.0-0029882565 (Pubitemid 26226556)
8. Bartalena L., Bogazzi F., Tanda M. L., Manetti L., Dell'Unto E., Martino E., Cigarette smoking and the thyroid. European Journal of Endocrinology 1995 133 5 507 512 2-s2.0-0028809714
9. Emiliano A. B., Governale L., Parks M., Cooper D. S., Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. The Journal of Clinical Endocrinology & Metabolism 2010 95 5 2227 2233 2-s2.0-77952767922 10.1210/jc.2009-2752
10. Marcocci C., claudio.marcocci@med.unipi.it Kahaly G. J., Krassas G. E., Bartalena L., Prummel M., Stahl M., Altea M. A., Nardi M., Pitz S., Boboridis K., Sivelli P., Von Arx G., Mourits M. P., Baldeschi L., Bencivelli W., Wiersinga W., Selenium and the course of mild Graves' orbitopathy. The New England Journal of Medicine 2011 364 20 1920 1931 10.1056/NEJMoa1012985
11. Rotondi M., Lazzeri E., Romagnani P., Serio M., Role for interferon- γ inducible chemokines in endocrine autoimmunity: an expanding field. Journal of Endocrinological Investigation 2003 26 2 177 180 2-s2.0-0037316394 (Pubitemid 36503068)
12. Prabhakar B. S., Bahn R. S., Smith T. J., Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocrine Reviews 2003 24 6 802 835 2-s2.0-0346057834 10.1210/er.2002-0020 (Pubitemid 38067700)
13. Bahn R. S., Pathophysiology of Graves' ophthalmopathy: the cycle of disease. The Journal of Clinical Endocrinology & Metabolism 2003 88 5 1939 1946 (Pubitemid 36549860)
14. Smith T. J., terrysmi@med.umich.edu Pathogenesis of Graves' orbitopathy: a 2010 update. Journal of Endocrinological Investigation 2010 33 6 414 421
15. Bahn R.S., Mechanisms of disease-Graves' ophthalmopathy. The New England Journal of Medicine 2010 362 726 738
16. Wiersinga W. M., w.m.wiersinga@amc.uva.nl Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? The Journal of Clinical Endocrinology & Metabolism 2011 96 8 2386 2394 10.1210/jc.2011-0307
17. Bartalena L., Tanda M. L., Piantanida E., Lai A., Oxidative stress and Graves' ophthalmopathy: in vitro studies and therapeutic implications. BioFactors 2003 19 3-4 155 163 2-s2.0-0842264910 (Pubitemid 38175119)
18. Aslan M., m.aslan301@mynet.com Cosar N., Celik H., Aksoy N., Dulger A. C., Begenik H., Soyoral Y. U., Kucukoglu M. E., Selek S., Evaluation of oxidative status in patients with hyperthyroidism. Endocrine 2011 40 2 285 289 10.1007/s12020-011-9472-3
19. Kohler H., Jenzer H., Interaction of lactoperoxidase with hydrogen peroxide. Formation of enzyme intermediates and generation of free radicals. Free Radical Biology & Medicine 1989 6 3 323 339 2-s2.0-0024595854 (Pubitemid 19076498)
20. Ademolu E., Özbey N., Erbil Y., Tanrikulu S., Barbaros U., Yanik B. T., Bozbora A., Özarmaan S., Determination of oxidative stress in thyroid tissue and plasma of patients with Graves' disease. European Journal of Internal Medicine 2006 17 8 545 550 2-s2.0-35348992554 10.1016/j.ejim.2006.04.013 (Pubitemid 44827700)
21. Tsai C. C., Wu S. B., Cheng C. Y., Kao S. C., Kau H. C., Chiou S. H., Hsu W. M., Wei Y. H., Increased oxidative DNA damage, lipid peroxidation, and reactive oxygen species in cultured orbital fibroblasts from patients with Graves ophthalmopathy: evidence that oxidative stress has a role in this disorder. Eye 2010 24 9 1520 1525 2-s2.0-77956607518 10.1038/eye.2010.31
22. Tomlinson J. W., Durrani O. M., Bujalska I. J., Gathercole L. L., Tomlins P. J., Reuser T. T. Q., Rose G. E., Curnow S. J., Stewart P. M., Walker E. A., Rauz S., s.rauz@bham.ac.uk The role of 11 β -hydroxysteroid dehydrogenase 1 in adipogenesis in thyroid-associated ophthalmopathy. The Journal of Clinical Endocrinology & Metabolism 2010 95 1 398 406 10.1210/jc.2009-0873
23. Eckstein A. K., Plicht M., Lax H., Neuhäuser M., Mann K., Lederbogen S., Heckmann C., Esser J., Morgenthaler N. G., Thyrotropin receptor autoantibodies are independent risk factors for graves' ophthalmopathy and help to predict severity and outcome of the disease. The Journal of Clinical Endocrinology & Metabolism 2006 91 9 3464 3470 2-s2.0-33748740658 10.1210/jc.2005-2813 (Pubitemid 44402120)
24. Orgiazzi J., Madec A. M., Reduction of the risk of relapse after withdrawal of medical therapy for Graves' disease. Thyroid 2002 12 10 849 853 2-s2.0-0036808951 (Pubitemid 35332988)
25. Stan M. N., Bahn R. S., Risk factors for development or deterioration of Graves' ophthalmopathy. Thyroid 2010 20 7 777 783 2-s2.0-78349257108
26. Bartalena L., Marcocci C., Bogazzi F., Panicucci M., Lepri A., Pinchera A., Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. The New England Journal of Medicine 1989 321 20 1349 1352 2-s2.0-0024449633 (Pubitemid 19284190)
27. Lai A., Sassi L., Compri E., Marino F., Sivelli P., Piantanida E., Tanda M. L., Bartalena L., Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study. The Journal of Clinical Endocrinology & Metabolism 2010 95 3 1333 1337 2-s2.0-77749239827 10.1210/jc.2009-2130
28. Bartalena L., Marcocci C., Bogazzi F., Manetti L., Tanda M. L., Dell'Unto E., Bruno-Bossio G., Nardi M., Bartolomei M. P., Lepri A., Rossi G., Martino E., Pinchera A., Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. The New England Journal of Medicine 1998 338 2 73 78 2-s2.0-0032495543 10.1056/NEJM199801083380201 (Pubitemid 28042269)
29. Bartalena L., luigi.bartalena@uninsubria.it The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy. The Journal of Clinical Endocrinology & Metabolism 2011 96 3 592 599 10.1210/jc.2010-2329
30. Laurberg P., peter.laurberg@rn.dk Berman D. C., Andersen S., Pedersen I. B., Sustained control of graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe graves' orbitopathy. Thyroid 2011 21 9 951 956 10.1089/thy.2011.0039
31. Elbers L., l.p.elbers@amc.uva.nl Mourits M., Wiersinga W., Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy. Thyroid 2011 21 3 279 283 10.1089/thy.2010.0181
32. Bartalena L., Pinchera A., Marcocci C., Management of graves' ophthalmopathy: reality and perspectives. Endocrine Reviews 2000 21 2 168 199 2-s2.0-0034454231 10.1210/er.21.2.168 (Pubitemid 32275594)
33. Mourits M. P., Koornneef L., Wiersinga W. M., Prummel M. F., Berghout A., van der Gaag R., Clinical criteria for the assessment of disease activity in Graves' ophthalmology: a novel approach. British Journal of Ophthalmology 1989 73 8 639 644 2-s2.0-0024406924 (Pubitemid 19202075)
34. Vannucchi G., Campi I., Bonomi M., Covelli D., Dazzi D., Currò N., Simonetta S., Bonara P., Persani L., Guastella C., Wall J., Beck-Peccoz P., Salvi M., Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. Clinical & Experimental Immunology 2010 161 3 436 443 2-s2.0-77955729037 10.1111/j.1365-2249.2010.04191.x
35. Salvi M., Vannucchi G., Campi I., Beck-Peccoz P., Rituximab in the treatment of thyroid eye disease: science fiction? Orbit 2009 28 4 251 255 2-s2.0-70350694454 10.3109/01676830903104611
36. Bouzas E. A., Karadimas P., Mastorakos G., Koutras D. A., Antioxidant agents in the treatment of Graves' ophthalmopathy. American Journal of Ophthalmology 2000 129 5 618 622 2-s2.0-0034126183 10.1016/S0002-9394(00)00359-7 (Pubitemid 30323727)
37. Vrca V. B., Skreb F., Cepelak I., Romic Z., Mayer L., Supplementation with antioxidants in the treatment of Graves' disease; the effect on glutathione peroxidase activity and concentration of selenium. Clinica Chimica Acta 2004 341 1-2 55 63 2-s2.0-1142309611 10.1016/j.cccn.2003.10.028 (Pubitemid 38210314)
38. Wertenbruch T., Willenberg H. S., Sagert C., Nguyen T. B. T., Bahlo M., Feldkamp J., Groeger C., Hermsen D., Scherbaum W. A., Schott M., Serum selenium levels in patients with remission and relapse of Graves' disease. Medicinal Chemistry 2007 3 3 281 284 2-s2.0-34248666740 10.2174/157340607780620662 (Pubitemid 46773944)
39. Duntas L. H., Selenium and the thyroid: a close-knit connection. The Journal of Clinical Endocrinology & Metabolism 2010 95 12 5180 5188 2-s2.0-78650056003 10.1210/jc.2010-0191
40. Kihara M., Kontani K., Yamauchi A., Miyauchi A., Nakamura H., Yodoi J., Yokomise H., Expression of thioredoxin in patients with Graves' disease. International Journal of Molecular Medicine 2005 15 5 795 799 2-s2.0-22844438325
41. Venditti P., Di Meo S., De Leo T., Effect of thyroid state on characteristics determining the susceptibility to oxidative stress of mitochondrial fractions from rat liver. Cellular Physiology and Biochemistry 1996 6 5 283 295 2-s2.0-0029994180 (Pubitemid 26419329)
42. Abalovich M., Llesuy S., Gutierrez S., Repetto M., Peripheral parameters of oxidative stress in Graves' disease: the effects of methimazole and 131 iodine treatments. Clinical Endocrinology 2003 59 3 321 327 2-s2.0-0042827455 10.1046/j.1365-2265.2003.01850.x (Pubitemid 37046985)
43. Duntas L. H., The role of selenium in thyroid autoimmunity and cancer. Thyroid 2006 16 5 455 460 2-s2.0-33745188243 10.1089/thy.2006.16.455
44. Seven A., Seymen O., Hatemi S., Hatemi H., Yiit G., Candan G., Antioxidant status in experimental hyperthyroidism: effect of vitamin E supplementation. Clinica Chimica Acta 1996 256 1 65 74 2-s2.0-0030577469 10.1016/S0009-8981(96)06415-7 (Pubitemid 26402975)
45. Barnes P. J., Karin M., Nuclear factor- κ Ba pivotal transcription factor in chronic inflammatory diseases. The New England Journal of Medicine 1997 336 15 1066 1071 2-s2.0-0030615201 10.1056/NEJM199704103361506 (Pubitemid 27163860)
46. Zhang F., Yu W., Hargrove J. L., Greenspan P., Dean R. G., Taylor E. W., Hartle D. K., Inhibition of TNF- α induced ICAM-1, VCAM-1 and E-selectin expression by selenium. Atherosclerosis 2002 161 2 381 386 2-s2.0-0036121303 10.1016/S0021-9150(01)00672-4 (Pubitemid 34219191)
47. Xia N., Zhou S., Liang Y., Xiao C., Shen H., Pan H., Deng H., Wang N., Li Q. Q., CD4+ T cells and the Th1/Th2 imbalance are implicated in the pathogenesis of Graves' ophthalmopathy. International Journal of Molecular Medicine 2006 17 5 911 916 2-s2.0-33750598841
48. Chang Y., Piao S. L., Gao S., Zheng D. M., Regulatory effects of micronutrient complex on the expression of Th1 and Th2 cytokines in diabetic C57BL mice. Wei Sheng Yan Jiu 2005 34 1 64 66 2-s2.0-33745199436
49. Hiromatsu Y., Yang D., Bednarczuk T., Miyake I., Nonaka K., Inoue Y., Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. The Journal of Clinical Endocrinology & Metabolism 2000 85 3 1194 1199 2-s2.0-0034453080 10.1210/jc.85.3.1194 (Pubitemid 32269371)
50. Li Y. B., Han J. Y., Jiang W., Wang J., Selenium inhibits high glucose-induced cyclooxygenase-2 and P-selectin expression in vascular endothelial cells. Molecular Biology Reports 2011 38 4 2301 2306 2-s2.0-78049398042 10.1007/s11033-010-0362-1
51. Konuk E. B. Y., Konuk O., Misirlioglu M., Menevse A., Unal M., Expression of cyclooxygenase-2 in orbital fibroadipose connective tissues of Graves' ophthalmopathy patients. European Journal of Endocrinology 2006 155 5 681 685 2-s2.0-33845263695 10.1530/eje.1.02280 (Pubitemid 44857491)